Candidiasis, Invasive: Clinical Trials

10 trials for Candidiasis, Invasive, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 210Completed 10

Follow Candidiasis, Invasive: new trials by email Literature Review of Candidiasis, Invasive trials Research Report on Candidiasis, Invasive

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
Interferon Gamma-1B - Candidemia
Phase 2CompletedRadboud University Medical Center652022-03-312026-06-22
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
APX001 - Candidemia, Invasive Candidiases
Phase 2CompletedBasilea Pharmaceutica92019-12-132025-09-16
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
APX001 - Candidemia
Phase 2CompletedBasilea Pharmaceutica212018-10-032025-09-16
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
CD101, Caspofungin, Fluconazole - Candidemia, Mycoses
Phase 2CompletedCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2072016-07-262020-12-08
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
Micafungin - Candidiasis, Systemic, Candida Meningitis
Phase 2CompletedAstellas Pharma Global Development, Inc.352015-05-302024-11-18
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive
Phase 2CompletedScynexis, Inc.272014-09-012024-06-25
A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)
Caspofungin - Candidiasis, Esophageal, Candidiasis, Invasive
Phase 2CompletedMerck Sharp & Dohme LLC202010-07-062018-08-27
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection
voriconazole (Vfend) - Candidiasis, Candidemia
Phase 2CompletedPfizer402008-12-012011-01-28
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Anidulafungin, VER002 - Candidiasis
Phase 2CompletedPfizer1202001-08-012008-10-21
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
FK463 - Candidiasis
Phase 2CompletedAstellas Pharma Inc751999-02-272018-01-10

Narrower conditions

Candidemia (8)  ·  Candidiasis (5)  ·  Mycoses (2)  ·  Aspergillosis (1)  ·  Fungemia (1)

Broader conditions

Bacterial Infections and Mycoses (10)  ·  Infections (10)  ·  Invasive Fungal Infections (10)  ·  Inflammation (8)  ·  Mycoses (8)  ·  Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Sepsis (8)  ·  Systemic Inflammatory Response Syndrome (8)  ·  Fungemia (7)  ·  Candidiasis (5)

Interventions

Micafungin (3)  ·  Caspofungin (2)  ·  Fluconazole (2)  ·  Anidulafungin (1)  ·  Injections (1)  ·  Voriconazole (1)  ·  ibrexafungerp (1)  ·  interferon gamma-1b (1)

Sponsors

Basilea Pharmaceutica (2)  ·  Pfizer (2)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Astellas Pharma Inc (1)  ·  Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Radboud University Medical Center (1)  ·  Scynexis, Inc. (1)

Countries

United States (6)  ·  Germany (4)  ·  Italy (3)  ·  Spain (3)  ·  Belgium (2)  ·  Greece (2)  ·  Romania (2)  ·  Austria (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  El Salvador (1)  ·  France (1)  ·  Guatemala (1)  ·  Honduras (1)  ·  Hungary (1)

Top investigators

Marc Engelhardt (2)  ·  David Angulo, MD (1)  ·  Taylor Sandison, MD MPH (1)

Results publications

PMID 25701307, PMID 32955088, PMID 33558294, PMID 37022196, PMID 37596890, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 41940006

NIH funding

2014 (1), 2015 (1)